BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van der Vries E, Stittelaar KJ, van Amerongen G, Veldhuis Kroeze EJ, de Waal L, Fraaij PL, Meesters RJ, Luider TM, van der Nagel B, Koch B, Vulto AG, Schutten M, Osterhaus AD. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog 2013;9:e1003343. [PMID: 23717200 DOI: 10.1371/journal.ppat.1003343] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Cho HJ, Jang JW, Ko SY, Choi SH, Lim CS, An SSA. Evaluation and verification of the nanosphere Verigene RV+ assay for detection of influenza A/B and H1/H3 subtyping: Evaluation and Verification of the Nanosphere Verigene RV+ Assay. J Med Virol 2015;87:18-24. [DOI: 10.1002/jmv.23970] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
2 Roosenhoff R, Reed V, Kenwright A, Schutten M, Boucher CA, Monto A, Clinch B, Kumar D, Whitley R, Nguyen-Van-Tam JS, Osterhaus ADME, Fouchier RAM, Fraaij PLA. Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clin Infect Dis 2020;71:1186-94. [PMID: 31560055 DOI: 10.1093/cid/ciz939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kaufman SS, Green KY, Korba BE. Treatment of norovirus infections: moving antivirals from the bench to the bedside. Antiviral Res 2014;105:80-91. [PMID: 24583027 DOI: 10.1016/j.antiviral.2014.02.012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 6.9] [Reference Citation Analysis]
4 Ison MG, Hirsch HH. Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs. Clin Microbiol Rev 2019;32:e00042-19. [PMID: 31511250 DOI: 10.1128/CMR.00042-19] [Cited by in Crossref: 41] [Cited by in F6Publishing: 21] [Article Influence: 13.7] [Reference Citation Analysis]
5 Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, Ryder AB, Miller MS, Rose JK, Palese P, García-Sastre A, Albrecht RA. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 2014;88:3432-42. [PMID: 24403585 DOI: 10.1128/JVI.03004-13] [Cited by in Crossref: 107] [Cited by in F6Publishing: 83] [Article Influence: 13.4] [Reference Citation Analysis]
6 Eden JS, Chisholm RH, Bull RA, White PA, Holmes EC, Tanaka MM. Persistent infections in immunocompromised hosts are rarely sources of new pathogen variants. Virus Evol 2017;3:vex018. [PMID: 28775894 DOI: 10.1093/ve/vex018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
7 Oh DY, Hurt AC. Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness. Front Microbiol 2016;7:80. [PMID: 26870031 DOI: 10.3389/fmicb.2016.00080] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
8 Mitha E, Krivan G, Jacobs F, Nagler A, Alrabaa S, Mykietiuk A, Kenwright A, Le Pogam S, Clinch B, Vareikiene L. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. Infect Dis Ther 2019;8:613-26. [PMID: 31667696 DOI: 10.1007/s40121-019-00271-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
9 Stittelaar KJ, de Waal L, van Amerongen G, Veldhuis Kroeze EJ, Fraaij PL, van Baalen CA, van Kampen JJ, van der Vries E, Osterhaus AD, de Swart RL. Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts. Viruses 2016;8:E168. [PMID: 27314379 DOI: 10.3390/v8060168] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
10 Laplante J, St George K. Antiviral resistance in influenza viruses: laboratory testing. Clin Lab Med 2014;34:387-408. [PMID: 24856534 DOI: 10.1016/j.cll.2014.02.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, Ito M, Nakajima N, Yamada S, Imai M, Kawakami E, Tomita Y, Fukuyama S, Itoh Y, Ogasawara K, Lopes TJS, Watanabe T, Moncla LH, Hasegawa H, Friedrich TC, Neumann G, Kawaoka Y. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques. J Infect Dis 2017;216:582-93. [PMID: 28931216 DOI: 10.1093/infdis/jix296] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
12 Hawkinson DJ, Ison MG. Respiratory Viruses: Influenza, RSV, and Adenovirus in Kidney Transplantation. Semin Nephrol 2016;36:417-27. [PMID: 27772626 DOI: 10.1016/j.semnephrol.2016.05.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
13 Veldhuis Kroeze E, Bauer L, Caliendo V, van Riel D. In Vivo Models to Study the Pathogenesis of Extra-Respiratory Complications of Influenza A Virus Infection. Viruses 2021;13:848. [PMID: 34066589 DOI: 10.3390/v13050848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Garnacho-Montero J, León-Moya C, Gutiérrez-Pizarraya A, Arenzana-Seisdedos A, Vidaur L, Guerrero JE, Gordón M, Martín-Loeches I, Rodriguez A; on Behalf GETGAG Study Group. Clinical characteristics, evolution, and treatment-related risk factors for mortality among immunosuppressed patients with influenza A (H1N1) virus admitted to the intensive care unit. J Crit Care 2018;48:172-7. [PMID: 30216935 DOI: 10.1016/j.jcrc.2018.08.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Reperant LA, Moesker FM, Osterhaus AD. Influenza: from zoonosis to pandemic. ERJ Open Res 2016;2:00013-2016. [PMID: 27730163 DOI: 10.1183/23120541.00013-2016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
16 Fukao K, Ando Y, Noshi T, Kitano M, Noda T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS One 2019;14:e0217307. [PMID: 31107922 DOI: 10.1371/journal.pone.0217307] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
17 Roosenhoff R, van der Vries E, van der Linden A, van Amerongen G, Stittelaar KJ, Smits SL, Schutten M, Fouchier RAM. Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance. PLoS One 2018;13:e0200849. [PMID: 30024940 DOI: 10.1371/journal.pone.0200849] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
18 Lin CH, Yang CY, Ou SC, Wang M, Lo CY, Tsai TL, Wu HY. The Impacts of Antivirals on the Coronavirus Genome Structure and Subsequent Pathogenicity, Virus Fitness and Antiviral Design. Biomedicines 2020;8:E376. [PMID: 32987828 DOI: 10.3390/biomedicines8100376] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013;3:521-30. [PMID: 23978327 DOI: 10.1016/j.coviro.2013.07.007] [Cited by in Crossref: 232] [Cited by in F6Publishing: 222] [Article Influence: 25.8] [Reference Citation Analysis]
20 Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. Clin Immunol 2020;220:108588. [PMID: 32905851 DOI: 10.1016/j.clim.2020.108588] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 16.0] [Reference Citation Analysis]
21 Bruminhent J, Deziel PJ, Wotton JT, Binnicker MJ, Razonable RR. Prolonged shedding of pandemic influenza A (H1N1) 2009 virus in a pancreas-after-kidney transplant recipient. J Clin Virol 2014;61:302-4. [PMID: 25081940 DOI: 10.1016/j.jcv.2014.07.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
22 Marathe BM, Mostafa HH, Vogel P, Pascua PNQ, Jones JC, Russell CJ, Webby RJ, Govorkova EA. A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment. Antiviral Res 2017;148:20-31. [PMID: 29100887 DOI: 10.1016/j.antiviral.2017.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
23 D'Alessio F, Koopman G, Houard S, Remarque EJ, Stockhofe N, Engelhardt OG. Workshop report: Experimental animal models for universal influenza vaccines. Vaccine 2018;36:6895-901. [PMID: 30340885 DOI: 10.1016/j.vaccine.2018.10.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Ison MG, Hayden FG, Hay AJ, Gubareva LV, Govorkova EA, Takashita E, McKimm-Breschkin JL. Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Res 2021;194:105158. [PMID: 34363859 DOI: 10.1016/j.antiviral.2021.105158] [Reference Citation Analysis]
25 Belser JA, Eckert AM, Tumpey TM, Maines TR. Complexities in Ferret Influenza Virus Pathogenesis and Transmission Models. Microbiol Mol Biol Rev 2016;80:733-44. [PMID: 27412880 DOI: 10.1128/MMBR.00022-16] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
26 Siegers JY, van den Brand JM, Leijten LM, van de Bildt MM, van Run PR, van Amerongen G, Stittelaar KJ, Koopmans MP, Osterhaus AD, Kuiken T, van Riel D. Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve. J Infect Dis 2016;214:516-24. [PMID: 27448390 DOI: 10.1093/infdis/jiw123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
27 Sturm S, Lemenuel-Diot A, Patel K, Gibiansky L, Bhardwaj R, Smith PF, Dang S, Zwanziger E, Nasmyth-Miller C, Ravva P. Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. Br J Clin Pharmacol 2021;87:1359-68. [PMID: 32808306 DOI: 10.1111/bcp.14523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Lewis NS, Verhagen JH, Javakhishvili Z, Russell CA, Lexmond P, Westgeest KB, Bestebroer TM, Halpin RA, Lin X, Ransier A, Fedorova NB, Stockwell TB, Latorre-Margalef N, Olsen B, Smith G, Bahl J, Wentworth DE, Waldenström J, Fouchier RAM, de Graaf M. Influenza A virus evolution and spatio-temporal dynamics in Eurasian wild birds: a phylogenetic and phylogeographical study of whole-genome sequence data. J Gen Virol 2015;96:2050-60. [PMID: 25904147 DOI: 10.1099/vir.0.000155] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
29 Hadjichrysanthou C, Cauët E, Lawrence E, Vegvari C, de Wolf F, Anderson RM. Understanding the within-host dynamics of influenza A virus: from theory to clinical implications. J R Soc Interface 2016;13:20160289. [PMID: 27278364 DOI: 10.1098/rsif.2016.0289] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
30 Moore IN, Lamirande EW, Paskel M, Donahue D, Kenney H, Qin J, Subbarao K. Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume. J Virol 2014;88:13879-91. [PMID: 25187553 DOI: 10.1128/JVI.02341-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
31 Rogers MB, Song T, Sebra R, Greenbaum BD, Hamelin ME, Fitch A, Twaddle A, Cui L, Holmes EC, Boivin G, Ghedin E. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection. mBio 2015;6:e02464-14. [PMID: 25852163 DOI: 10.1128/mBio.02464-14] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
32 Pascua PNQ, Mostafa HH, Marathe BM, Vogel P, Russell CJ, Webby RJ, Govorkova EA. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Sci Rep 2017;7:7345. [PMID: 28779075 DOI: 10.1038/s41598-017-07433-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
33 Baz M, Carbonneau J, Rhéaume C, Cavanagh MH, Boivin G. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses 2018;10:E610. [PMID: 30400276 DOI: 10.3390/v10110610] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
34 Smits SL, Raj VS, Oduber MD, Schapendonk CM, Bodewes R, Provacia L, Stittelaar KJ, Osterhaus AD, Haagmans BL. Metagenomic analysis of the ferret fecal viral flora. PLoS One 2013;8:e71595. [PMID: 23977082 DOI: 10.1371/journal.pone.0071595] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
35 Anastasiou OE, Hüsing A, Korth J, Theodoropoulos F, Taube C, Jöckel KH, Stang A, Dittmer U. Seasonality of Non-SARS, Non-MERS Coronaviruses and the Impact of Meteorological Factors. Pathogens 2021;10:187. [PMID: 33572306 DOI: 10.3390/pathogens10020187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 McKie AM, Jones TPW, Sykes C. Prolonged viral shedding in an immunocompetent patient with COVID-19. BMJ Case Rep 2020;13:e237357. [PMID: 33012717 DOI: 10.1136/bcr-2020-237357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
37 Lim VW, Tudor Car L, Leo YS, Chen MI, Young B. Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and meta-analysis. Influenza Other Respir Viruses 2020;14:226-36. [PMID: 31733048 DOI: 10.1111/irv.12699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
38 Rijsbergen LC, Schmitz KS, Begeman L, Drew-Bear J, Gommers L, Lamers MM, Greninger AL, Haagmans BL, Porotto M, de Swart RL, Moscona A, de Vries RD. Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets. mBio 2022;:e0383121. [PMID: 35164568 DOI: 10.1128/mbio.03831-21] [Reference Citation Analysis]
39 Mc Mahon A, Martin-Loeches I. The pharmacological management of severe influenza infection - 'existing and emerging therapies'. Expert Rev Clin Pharmacol 2017;10:81-95. [PMID: 27797595 DOI: 10.1080/17512433.2017.1255550] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
40 Korenkov D, Isakova-sivak I, Rudenko L. Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine. Expert Review of Vaccines 2018;17:977-87. [DOI: 10.1080/14760584.2018.1541407] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
41 Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, Barbian K, Judson SD, Fischer ER, Martens C, Bowden TA, de Wit E, Riedo FX, Munster VJ. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020;183:1901-1912.e9. [PMID: 33248470 DOI: 10.1016/j.cell.2020.10.049] [Cited by in Crossref: 192] [Cited by in F6Publishing: 194] [Article Influence: 96.0] [Reference Citation Analysis]
42 Calabrese C, Lehman B. COVID-19: a primer for the rheumatologist: management of patients and care settings. Curr Opin Rheumatol 2020;32:429-33. [PMID: 32744823 DOI: 10.1097/BOR.0000000000000732] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Ruiz SI, Zumbrun EE, Nalca A. Animal Models of Human Viral Diseases. Animal Models for the Study of Human Disease. Elsevier; 2017. pp. 853-901. [DOI: 10.1016/b978-0-12-809468-6.00033-4] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
44 Kitano M, Matsuzaki T, Oka R, Baba K, Noda T, Yoshida Y, Sato K, Kiyota K, Mizutare T, Yoshida R, Sato A, Kamimori H, Shishido T, Naito A. The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets. Influenza Other Respir Viruses 2020;14:710-9. [PMID: 32533654 DOI: 10.1111/irv.12760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Xue KS, Moncla LH, Bedford T, Bloom JD. Within-Host Evolution of Human Influenza Virus. Trends Microbiol 2018;26:781-93. [PMID: 29534854 DOI: 10.1016/j.tim.2018.02.007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 13.5] [Reference Citation Analysis]
46 Reperant LA, Grenfell BT, Osterhaus AD. Quantifying the risk of pandemic influenza virus evolution by mutation and re-assortment. Vaccine 2015;33:6955-66. [PMID: 26603954 DOI: 10.1016/j.vaccine.2015.10.056] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
47 de Graaf M, Beck R, Caccio SM, Duim B, Fraaij P, Le Guyader FS, Lecuit M, Le Pendu J, de Wit E, Schultsz C. Sustained fecal-oral human-to-human transmission following a zoonotic event. Curr Opin Virol 2017;22:1-6. [PMID: 27888698 DOI: 10.1016/j.coviro.2016.11.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
48 Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood 2016;127:2682-92. [PMID: 26968533 DOI: 10.1182/blood-2016-01-634873] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
49 Roosenhoff R, Schutten M, Reed V, Clinch B, van der Linden A, Fouchier RAM, Fraaij PLA. Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS). Antiviral Res 2021;189:105060. [PMID: 33713731 DOI: 10.1016/j.antiviral.2021.105060] [Reference Citation Analysis]
50 Farrukee R, Hurt AC. Antiviral Drugs for the Treatment and Prevention of Influenza. Curr Treat Options Infect Dis 2017;9:318-32. [DOI: 10.1007/s40506-017-0129-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
51 Kates OS, Stohs EJ, Pergam SA, Rakita RM, Michaels MG, Wolfe CR, Danziger-Isakov L, Ison MG, Blumberg EA, Razonable RR, Gordon EJ, Diekema DS. The limits of refusal: An ethical review of solid organ transplantation and vaccine hesitancy. Am J Transplant 2021;21:2637-45. [PMID: 33370501 DOI: 10.1111/ajt.16472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Hundakova A, Leva L, Toman M, Knotek Z. A ferret model of immunosuppression induced with dexamethasone. Vet Immunol Immunopathol 2022;243:110362. [PMID: 34826685 DOI: 10.1016/j.vetimm.2021.110362] [Reference Citation Analysis]
53 Kim HM, Lee N, Kim MS, Kang C, Chung YS. Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea. Virol J 2020;17:94. [PMID: 32631440 DOI: 10.1186/s12985-020-01375-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Inagaki K, Song MS, Crumpton JC, DeBeauchamp J, Jeevan T, Tuomanen EI, Webby RJ, Hakim H. Correlation Between the Interval of Influenza Virus Infectivity and Results of Diagnostic Assays in a Ferret Model. J Infect Dis 2016;213:407-10. [PMID: 26068783 DOI: 10.1093/infdis/jiv331] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
55 Goldhill DH, Barclay WS. 2020 Hindsight: Should evolutionary virologists have expected the unexpected during a pandemic? Evolution 2021. [PMID: 34342897 DOI: 10.1111/evo.14317] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Honce R, Schultz-Cherry S. They are what you eat: Shaping of viral populations through nutrition and consequences for virulence. PLoS Pathog 2020;16:e1008711. [PMID: 32790755 DOI: 10.1371/journal.ppat.1008711] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Starbæk SMR, Brogaard L, Dawson HD, Smith AD, Heegaard PMH, Larsen LE, Jungersen G, Skovgaard K. Animal Models for Influenza A Virus Infection Incorporating the Involvement of Innate Host Defenses: Enhanced Translational Value of the Porcine Model. ILAR Journal 2018;59:323-37. [DOI: 10.1093/ilar/ily009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 de Graaf M, van Beek J, Koopmans MPG. Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol 2016;14:421-33. [DOI: 10.1038/nrmicro.2016.48] [Cited by in Crossref: 174] [Cited by in F6Publishing: 157] [Article Influence: 29.0] [Reference Citation Analysis]
59 de Waal L, Smits SL, Veldhuis Kroeze EJB, van Amerongen G, Pohl MO, Osterhaus ADME, Stittelaar KJ. Transmission of Human Respiratory Syncytial Virus in the Immunocompromised Ferret Model. Viruses 2018;10:E18. [PMID: 29301313 DOI: 10.3390/v10010018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Oh DY, Lowther S, McCaw JM, Sullivan SG, Leang SK, Haining J, Arkinstall R, Kelso A, Mcvernon J, Barr IG, Middleton D, Hurt AC. Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. J Antimicrob Chemother 2014;69:2458-69. [PMID: 24840623 DOI: 10.1093/jac/dku146] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
61 Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, Fry AM, Gubareva LV. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses. J Virol 2015;89:5419-26. [PMID: 25740997 DOI: 10.1128/JVI.03513-14] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
62 Widders A, Broom A, Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. Infect Dis Health. 2020;25:210-215. [PMID: 32473952 DOI: 10.1016/j.idh.2020.05.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 41.5] [Reference Citation Analysis]
63 Jansen AJG, Spaan T, Low HZ, Di Iorio D, van den Brand J, Tieke M, Barendrecht A, Rohn K, van Amerongen G, Stittelaar K, Baumgärtner W, Osterhaus A, Kuiken T, Boons GJ, Huskens J, Boes M, Maas C, van der Vries E. Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity. Blood Adv 2020;4:2967-78. [PMID: 32609845 DOI: 10.1182/bloodadvances.2020001640] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
64 Vidaña B, Martínez-Orellana P, Martorell JM, Baratelli M, Martínez J, Migura-Garcia L, Córdoba L, Pérez M, Casas I, Pozo F, Fraile L, Majó N, Montoya M. Differential Viral-Host Immune Interactions Associated with Oseltamivir-Resistant H275Y and Wild-Type H1N1 A(pdm09) Influenza Virus Pathogenicity. Viruses 2020;12:E794. [PMID: 32721992 DOI: 10.3390/v12080794] [Reference Citation Analysis]
65 van den Brand JM, Haagmans BL, van Riel D, Osterhaus AD, Kuiken T. The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. J Comp Pathol. 2014;151:83-112. [PMID: 24581932 DOI: 10.1016/j.jcpa.2014.01.004] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 10.9] [Reference Citation Analysis]
66 Belser JA, Eckert AM, Huynh T, Gary JM, Ritter JM, Tumpey TM, Maines TR. A Guide for the Use of the Ferret Model for Influenza Virus Infection. Am J Pathol 2020;190:11-24. [PMID: 31654637 DOI: 10.1016/j.ajpath.2019.09.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
67 Bohálová N, Cantara A, Bartas M, Kaura P, Šťastný J, Pečinka P, Fojta M, Mergny JL, Brázda V. Analyses of viral genomes for G-quadruplex forming sequences reveal their correlation with the type of infection. Biochimie 2021;186:13-27. [PMID: 33839192 DOI: 10.1016/j.biochi.2021.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
68 Reperant LA, Kuiken T, Grenfell BT, Osterhaus AD. The immune response and within-host emergence of pandemic influenza virus. Lancet 2014;384:2077-81. [PMID: 24767965 DOI: 10.1016/S0140-6736(13)62425-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]